跳至主要内容
临床试验/NCT00171444
NCT00171444已完成4 期

A 8-week Comparison, in a General Practice Setting, Between Two Treatment Strategies With Valsartan and Valsartan/HCTZ Aiming at Normalizing de Novo Hypertensive Patients Who Are Not Adequately Controlled With Their Monotherapy or Biotherapy Treatment or Experiencing Unacceptable Side-effects, According to Their Baseline Blood Pressure

Novartis0 个研究点目标入组 4,445 人开始时间: 2004年6月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
入组人数
4,445
主要终点
Blood pressure less than 140/90 mmHg in non-diabetic patients, or less than 130/80 mmHg in patients with diabetes or kidney disease, after 8 weeks

研究概览

简要总结

The purpose of the study is to determine whether a specific training of General Practitioners (Family Physicians) regarding the new official guidelines for the treatment of hypertension results in a higher control of high Blood pressure in their patient population.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • • Male or female patients >18 years of age
  • Hypertension defined by MSDBP ≥ 90 and /or MSSBP ≥ 140 mmHg for untreated patients, patients on diet and exercise, patients on current anti-hypertensive monotherapy or bitherapy treatment who remain uncontrolled or patients experiencing unacceptable side-effects,

排除标准

  • • Severe hypertension, secondary hypertension, type 1 diabetes mellitus
  • History of congestive heart failure, unstable coronary insufficiency, life threatening arrhythmia, significant valvular disease, second or third degree heart block etc.
  • Other protocol-defined exclusion criteria may apply.

结局指标

主要结局

Blood pressure less than 140/90 mmHg in non-diabetic patients, or less than 130/80 mmHg in patients with diabetes or kidney disease, after 8 weeks

次要结局

  • Change from baseline systolic blood pressure after 8 weeks
  • Change from baseline diastolic blood pressure after 8 weeks
  • Diastolic blood pressure less than 90 mmHg or reduction in diastolic blood pressure greater than 10 mmHg
  • Systolic blood pressure less than 140 mmHg or reduction in diastolic blood pressure greater than 15 mmHg

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

相似试验